Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

DiSH™ technology for rapid production of monoclonal antibodies now available from Enzo Life Sciences, Inc.

Enzo Life Sciences continues to enable drug and diagnostic development with our newest product, the Direct Selection of Hybridomas (DiSH™) Kit.

Monoclonal antibodies (mAb) are of high significance for the drug discovery market. In addition to their use as general purpose discovery reagents for detection and quantification of antigens, mAbs can function as biotherapeutic drug candidates, targeting disease-causing cells and critical biomarkers for highly specific diagnostic assays. Generation of mAbs can be a time-consuming process from immunization and fusion with myeloma cells, through selection and screening of antigen-specific hybridoma clones.

The DiSH™ technology patented by Abeome (Athens, GA) is an enhanced method for selecting antigen-specific hybridomas. Using a genetically engineered Sp2ab myeloma fusion partner, the DiSH system generates hybridomas that both secrete antigen-specific antibody and express the antibody on the cell surface. Once labeled, these hybridomas can easily be enriched from among a pool of hundreds of thousands of cells in a matter of hours using fluorescence activated cell sorting (FACS) or magnetic separation. This innovation shortens the clone selection phase by up to 75% compared to traditional limiting dilution protocols. The DiSH™ Kit is supplied with an easy-to-follow protocol, a validated cell line and all necessary media, reagents and controls.

With this complete kit, Enzo Life Sciences enables scientists to more rapidly detect novel antibodies for a variety of research and pharmaceutical applications.

For more information, or to order the DiSH™ Kit or other Enzo Life Sciences products, please visit us at or call us at 1-800-942-0430.

About Enzo Life Sciences

Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. The company is focused on providing innovative life science research reagents worldwide based on over 30 years of successful experience in building strong international market recognition, implementing outstanding operational capabilities, and establishing a state-of-the-art electronic information and ordering marketplace.

Enzo Life Sciences, Inc. is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of assay kits, libraries, proteins, antibodies, peptides, and small molecules provides life science researchers tools for target identification/validation, drug discovery, cellular analysis, high content analysis, gene expression analysis, nucleic acid detection, and protein biochemistry and detection.

New Product Release
Date: March 20, 2013

For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 145

Recommend this page

Keep in touch

©2022 Enzo Life Sciences, Inc.,